Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.07 | -0.46 | -0.04 |
| FCF Yield | -13.18% | -2.50% | 5.41% | -14.21% |
| EV / EBITDA | -3.23 | -23.91 | 11.05 | -3.34 |
| Quality | ||||
| ROIC | -33.49% | -23.70% | 2.76% | -63.93% |
| Gross Margin | 97.44% | 98.13% | 28.31% | -1,305.94% |
| Cash Conversion Ratio | 0.74 | 0.61 | 3.42 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -12.38% | 133.70% | 178.37% | -15.92% |
| Free Cash Flow Growth | -187.60% | -186.54% | 117.53% | -210.40% |
| Safety | ||||
| Net Debt / EBITDA | 2.69 | 10.83 | -21.68 | 1.49 |
| Interest Coverage | 0.00 | -101.96 | 4.06 | -75.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -730.44 | -577.43 | -14.10 | 78.31 |